Article
Malignant hyperthermia: a pharmacogenetic disease of Ca++ regulating proteins.
Current molecular medicine - 1 Jun 2002
Nelson Thomas E
Abstract excerpt
Malignant hyperthermia (MH) is a pharmacogenetic, life-threatening hypermetabolic syndrome in genetically predisposed individuals exposed to certain anesthetic agents. Discovered by Denborough and Lovell [1] in 1960, MH was associated with high mortality and morbidity as the cause was unknown and an effective treatment was unavailable. There is no classic clinical presentation of the syndrome, and the onset and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
